Another patent approval in the US related to Episurf Medical’s 3D-based damage assessment tool

Episurf Medical has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent being approved is within the area of 3D-based assessment of joint lesions, and complements Episurf Medical’s first US patent approval within that field, received in 2017.

“This patent covers important parts of our technology in the exciting field of medical imaging, where we are continuously working with protection of our intellectual properties” comments Pål Ryfors, CEO, Episurf Medical.  

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69


About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website:

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 7 February 2018.